Redhill Biopharma Ltd (RDHL) - Total Liabilities

Latest as of June 2025: $22.79 Million USD

Based on the latest financial reports, Redhill Biopharma Ltd (RDHL) has total liabilities worth $22.79 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Redhill Biopharma Ltd to assess how effectively this company generates cash.

Redhill Biopharma Ltd - Total Liabilities Trend (2010–2024)

This chart illustrates how Redhill Biopharma Ltd's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Redhill Biopharma Ltd's assets to evaluate the company's liquid asset resilience ratio.

Redhill Biopharma Ltd Competitors by Total Liabilities

The table below lists competitors of Redhill Biopharma Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Astrotech Corp NASDAQ:ASTC	USA	$4.18 Million
ROKMASTER Resources Corp V:RKR	Canada	CA$3.22 Million
Thunderstruck Resources Ltd V:AWE	Canada	CA$747.18K
Prophecy International Holdings Ltd AU:PRO	Australia	AU$15.82 Million
DSS Inc NYSE MKT:DSS	USA	$66.02 Million
Silver Grail Resources Ltd V:SVG	Canada	CA$412.12K
Pipe Works L. Girakian Profil S.A. AT:PROFK	Greece	€22.94 Million
Canadian Spirit Resources Inc V:SPI	Canada	CA$2.55 Million

Liability Composition Analysis (2010–2024)

This chart breaks down Redhill Biopharma Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Redhill Biopharma Ltd (RDHL) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.56	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-5.16	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	1.24	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Redhill Biopharma Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Redhill Biopharma Ltd (2010–2024)

The table below shows the annual total liabilities of Redhill Biopharma Ltd from 2010 to 2024.

Year	Total Liabilities	Change
2024-12-31	$22.73 Million	+8.33%
2023-12-31	$20.98 Million	-89.88%
2022-12-31	$207.27 Million	+20.29%
2021-12-31	$172.31 Million	+3.57%
2020-12-31	$166.38 Million	+1080.23%
2019-12-31	$14.10 Million	+25.59%
2018-12-31	$11.22 Million	-8.58%
2017-12-31	$12.28 Million	+6.66%
2016-12-31	$11.51 Million	+70.51%
2015-12-31	$6.75 Million	+75.58%
2014-12-31	$3.85 Million	+59.21%
2013-12-31	$2.42 Million	+124.03%
2012-12-31	$1.08 Million	-22.94%
2011-12-31	$1.40 Million	-88.44%
2010-12-31	$12.10 Million	--

About Redhill Biopharma Ltd

NASDAQ:RDHL USA Drug Manufacturers - Specialty & Generic

Market Cap

$5.55 Million

Market Cap Rank

#28279 Global

#5572 in USA

Share Price

$1.09

Change (1 day)

-0.46%

52-Week Range

$0.74 - $2.52

All Time High

$16290.00